Call us today 212-583-0100

ENZO Biochem Reports Phase II Data of Alequel™ for Management of Crohn’s Disease Trial Successfully

FARMINGDALE, NY, September 29, 2004 – Enzo Biochem, Inc. (NYSE:ENZ) today announced that the Phase II randomized double-blind study of Alequel™, the Company’s investigational therapeutic modality for the management of Crohn’s disease, successfully met its clinical endpoints and is moving forward with expanded studies.

The study showed that 67% of the drug-treated subjects had a clinical response compared with 43% of the placebo group. 58% of the drug treated group achieved clinical remission compared with 29% of placebo-treated subjects.

Thirty one subjects were enrolled and 26 completed the study – 12 in the drug-treatment group and 14 in the placebo group. The subjects were evaluated using the Crohn’s Disease Activity Index (CDAI), a standard measure of the severity of the disease, with higher scores indicating more severe disease activity. Clinical response is defined as a decrease in CDAI by 100 or more in two consecutive measurements over a 6-week period. Clinical remission is a decrease to a CDAI of 150 or less in two consecutive measurements.

Quality of life was assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ), an evaluation of health perception and function, completed by each subject before and at the end of treatment. The study drug group achieved a mean improvement of 43% in quality of life, while the placebo group achieved a mean improvement of 12%, indicating that the treated subjects not only responded to treatment, but that their quality of life improved greatly during the course of the trial.

FARMINGDALE, NY, September 29, 2004 – Enzo Biochem, Inc. (NYSE:ENZ) today announced that the Phase II randomized double-blind study of Alequel™, the Company’s investigational therapeutic modality for the management of Crohn’s disease, successfully met its clinical endpoints and is moving forward with expanded studies.

The study showed that 67% of the drug-treated subjects had a clinical response compared with 43% of the placebo group. 58% of the drug treated group achieved clinical remission compared with 29% of placebo-treated subjects.

Thirty one subjects were enrolled and 26 completed the study – 12 in the drug-treatment group and 14 in the placebo group. The subjects were evaluated using the Crohn’s Disease Activity Index (CDAI), a standard measure of the severity of the disease, with higher scores indicating more severe disease activity. Clinical response is defined as a decrease in CDAI by 100 or more in two consecutive measurements over a 6-week period. Clinical remission is a decrease to a CDAI of 150 or less in two consecutive measurements.

Quality of life was assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ), an evaluation of health perception and function, completed by each subject before and at the end of treatment. The study drug group achieved a mean improvement of 43% in quality of life, while the placebo group achieved a mean improvement of 12%, indicating that the treated subjects not only responded to treatment, but that their quality of life improved greatly during the course of the trial.